Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Eli Lilly and Company
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02760602CT.gov A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease | — | Terminated | — | — | — |
NCT02614131CT.gov A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD) | — | Terminated | — | — | — |
NCT01900665CT.gov Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo | — | Terminated | — | — | — |
NCT01760005CT.gov Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 | — | Active Not Recruiting | — | — | — |
NCT04623242CT.gov Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. | — | Completed | — | — | — |
NCT01127633CT.gov Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease | — | Terminated | — | — | — |
NCT01148498CT.gov A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's | — | Completed | — | — | — |
NCT00905372CT.gov Effect of LY2062430 on the Progression of Alzheimer's Disease | — | Completed | — | — | — |
NCT00904683CT.gov Effect of LY2062430 on the Progression of Alzheimer's Disease | — | Completed | — | — | — |
NCT00749216CT.gov Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT00329082CT.gov Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Alzheimer Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Solanezumab (this asset) | Eli Lilly and Company | P3 | BB · 64 |
| 4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE | Akiva Mintz | P4 | BBB |
| Memantine | Carnot Laboratories | P4 | BBB |
| Escitalopram | NYU Langone Health | P4 | BBB |
| Flortaucipir | Eli Radiopharma | P4 | BBB |
| Rivastigmine | Anhui Provincial Hospital | P4 | BBB |
| Florbetaben | National Institute of Mental Health (NIMH) | P4 | BBB |
| 6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS) | Anhui Provincial Hospital | P4 | BBB |
| Sertraline | AstraZeneca | P4 | BBB |
+42 more in the Alzheimer Disease cohort
Other indications for Solanezumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Familial Alzheimer Disease | — | P2/3 | CCC · 54 |
| Dementia | — | P2/3 | CCC · 53 |
| Cognitive Disorder | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Solanezumab in Alzheimer Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/solanezumab-alzheimer-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →